A review of the utilization of digital health technologies for college students with disabilities.

Objectives: The purpose of this study was to understand current research on the utilization of mobile health (mHealth) technologies for college students with disabilities.

Methods: We conducted a bibliometric analysis to understand the longitudinal research trends and dominant topics in mHealth research for college students. Next, we performed a scoping review to gain a more in-depth understanding of the current research on the use of mobile technologies for college students with disabilities.

Development of bark-based magnetic iron oxide particle (BMIOP), a bio-adsorbent for removal of arsenic (III) from water.

Novel low-cost bark-based magnetic iron oxide particles (BMIOPs) were synthesized and investigated for the removal of As(III) in drinking water. The synthesized BMIOP had a saturation magnetization value of 38.62 emug which was found to be enough for the magnetic separation of exhausted BMIOP after As(III) adsorption.

Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.

Stem cell leukemia/lymphoma syndrome (SCLL) is driven by constitutive activation of chimeric FGFR1 kinases generated by chromosome translocations. We have shown that FGFR inhibitors significantly suppress leukemia and lymphoma development in vivo, and cell viability in vitro. Since resistance to targeted therapies is a major reason for relapse, we developed FGFR1-overexpressing mouse and human cell lines that are resistant to the specific FGFR inhibitors AZD4547 and BGJ398, as well as non-specific inhibitors, such as ponatinib, TKI258 and E3810.

Removal of arsenic(III) from water by magnetic binary oxide particles (MBOP): Experimental studies on fixed bed column.

Magnetic binary oxide particles (MBOP) were prepared by template method using chitosan in the laboratory for the removal of As(III) from water. The prepared MBOP has super paramagnetic property which is sufficient for magnetic separation. Column study was performed at two different flow rates of 2.

SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.

Although over expression of chimeric FGFR1 kinase consistently leads to the development of AML in the rare Stem Cell Leukemia and Lymphoma syndrome, we now show that overexpression of FGFR1 is also seen in up to 20% of non-syndromic, de novo AML. To determine whether targeting FGFR1 in both of these AML subtypes can suppress leukemogenesis, we evaluated the effects of different FGFR1 inhibitors in a side-by-side comparison for their ability to affect in vitro proliferation in FGFR1 overexpressing murine and human cells lines. Three newly developed pan-FGFR inhibitors, AZD4547, BGJ398 and JNJ42756493, show a significantly improved efficacy over the more established FGFR inhibitors, PD173074 and TKI258.